COSMOS Pharmaceutical Corporation (3349.T)

Better than 2127.T's revenue of 44.08B.

Better than 2127.T's revenue growth rate of -0.13%.

Better than 2127.T's ebitda of 17.12B.

Better than 2127.T's ebit of 16.96B.

Better than 2127.T's total cash of 39.21B.

Better than 2127.T's receivables as percentage of revenue of 5.97%.

Better than 2127.T's capital expenditure of -48.01M.

Better than 2127.T's capex as percentage of revenue of -0.11%.

Better than 2127.T's weighted average cost of capital (wacc) of 6.72%.

Better than 2127.T's cost of equity of 6.82%.

Better than 2127.T's beta of 0.60.

Better than 2127.T's diluted shares outstanding of 317.20M.

Better than 2127.T's total equity of 221.09B.

Better than 2127.T's total capital of 226.49B.

Better than 2127.T's ebiat of 10.97B.

Better than 2127.T's unlevered free cash flow of 11.19B.

Better than 2127.T's terminal value of 313.01B.

Better than 2127.T's enterprise value of 279.06B.

Better than 2127.T's equity value of 312.87B.

Better than 2127.T's equity value per share of 986.34.